Dataset Information

Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update.

ABSTRACT:

Purpose

Renal cell carcinoma is an aggressive disease with a high mortality rate. Management has drastically changed with the new era of immunotherapy, and novel strategies are being developed; however, identifying systemic treatments is still challenging. This paper presents an update of the expert panel consensus from the Latin American Cooperative Oncology Group and the Latin American Renal Cancer Group on advanced renal cell carcinoma management in Brazil.

Methods

A panel of 34 oncologists and experts in renal cell carcinoma discussed and voted on the best options for managing advanced disease in Brazil, including systemic treatment of early and metastatic renal cell carcinoma as well as nonclear cell tumours. The results were compared with the literature and graded according to the level of evidence.

Results

Adjuvant treatments benefit patients with a high risk of recurrence after surgery, and the agents used are pembrolizumab and sunitinib, with a preference for pembrolizumab. Neoadjuvant treatment is exceptional, even in initially unresectable cases. First-line treatment is mainly based on tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs); the choice of treatment is based on the International Metastatic Database Consortium (IMCD) risk score. Patients at favourable risk receive ICIs in combination with TKIs. Patients classified as intermediate or poor risk receive ICIs, without preference for ICI + ICIs or ICI + TKIs. Data on nonclear cell renal cancer treatment are limited. Active surveillance has a place in treating favourable-risk patients. Either denosumab or zoledronic acid can be used for treating metastatic bone disease.

Conclusion

Immunotherapy and targeted therapy are the standards of care for advanced disease. The utilization and sequencing of these therapeutic agents hinge upon individual risk scores and responses to previous treatments. This consensus reflects a commitment to informed decision-making, drawn from professional expertise and evidence in the medical literature.

SUBMITTER: Soares A

PROVIDER: S-EPMC11003910 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update.

Soares Andrey A Monteiro Fernando Sabino Marques FSM da Trindade Karine Martins KM Silva Adriano Gonçalves E AGE Cardoso Ana Paula Garcia APG Sasse André Deeke AD Fay André P AP Carneiro André Paternò Castello Dias APCD Alencar Junior Antonio Machado AM de Andrade Mota Augusto César AC Santucci Bruno B da Motta Girardi Daniel D Herchenhorn Daniel D Araújo Daniel Vilarim DV Jardim Denis Leonardo DL Bastos Diogo Assed DA Rosa Diogo Rodrigues DR Schutz Fabio A FA Kater Fábio Roberto FR da Silva Marinho Felipe F Maluf Fernando Cotait FC de Oliveira Fernando Nunes Galvão FNG Vidigal Fernando F Morbeck Igor Alexandre Protzner IAP Rinck Júnior Jose Augusto JA Costa Leonardo Atem G A LAGA Maia Manuel Caitano Dias Ferreira MCDF Zereu Manuela M Freitas Marcelo Roberto Pereira MRP Dias Mariane Sousa Fontes MSF Tariki Milena Shizue MS Muniz Pamela P Beato Patrícia Medeiros Milhomem PMM Lages Paulo Sérgio Moraes PSM Velho Pedro Isaacsson PI de Carvalho Ricardo Saraiva RS Mariano Rodrigo Coutinho RC de Araújo Cavallero Sandro Roberto SR Oliveira Thiago Martins TM Souza Vinicius Carrera VC Smaletz Oren O de Cássio Zequi Stênio S

Journal of cancer research and clinical oncology 20240409 4

<h4>Purpose</h4>Renal cell carcinoma is an aggressive disease with a high mortality rate. Management has drastically changed with the new era of immunotherapy, and novel strategies are being developed; however, identifying systemic treatments is still challenging. This paper presents an update of the expert panel consensus from the Latin American Cooperative Oncology Group and the Latin American Renal Cancer Group on advanced renal cell carcinoma management in Brazil.<h4>Methods</h4>A panel of 3 ...[more]

PMID: 38594593

Similar Datasets

Project description:PurposeThe impact of the COVID-19 pandemic on Latin American radiation therapy services has not yet been widely assessed. In comparison to centers in Europe or the United States, the scarcity of data on these terms might impair design of adequate measures to ameliorate the pandemic's potential damage. The first survey-based analysis revealing regional information is herein presented.Methods and materialsFrom May 6 to May 30, 2020, the American Society for Radiation Oncology's COVID-19 Survey was distributed across Latin America with support of the local national radiation therapy societies. Twenty-six items, including facility demographic and financial characteristics, personnel and patient features, current and expected impact of the pandemic, and research perspectives, were included in the questionnaire.ResultsComplete responses were obtained from 115 (50%) of 229 practices across 15 countries. Only 2.6% of centers closed during the pandemic. A median of 4 radiation oncologists (1-27) and 9 (1-100) radiation therapists were reported per center. The median number of new patients treated in 2019 was 600 (24-6200). A median 8% (1%-90%) decrease in patient volume was reported, with a median of 53 patients (1-490) remaining under treatment. Estimated revenue reduction was 20% or more in 53% of cases. Shortage of personal protective equipment was reported in 51.3% of centers, and 27% reported personnel shortage due to COVID-19. Reported delays in treatment for low-risk entities included early stage breast cancer (42.6%), low-risk status prostate cancer (67%), and nonmalignant conditions (42.6%). Treatment of COVID-19 patients at designated treatment times and differentiated bunkers were reported in 22.6% and 10.4% of centers, respectively. Telehealth initiatives have been started in 64.3% of facilities to date for on-treatment (29.6%) and posttreatment (34.8%) patients.ConclusionsRegional information regarding COVID-19 pandemic in Latin America may help elucidate suitable intervention strategies for personnel and patients. Follow-up surveys will be performed to provide dynamic monitoring the pandemic's impact on radiation therapy services and adoption of ameliorating measures.

Dataset Information

Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update.

Purpose

Methods

Results

Conclusion

Publications

Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets